COVID-19 and Hematologic Malignancies: Single Institution Analysis

Introduction COVID-19 in patients with hematologic malignancies are poorly characterized. Theoretically, it is believed that patients with malignancies having a significant chance of succumbing to COVID-19 due to the immunosuppression from the disease and myelosuppression from the cancer therapy com...

Descripción completa

Detalles Bibliográficos
Autores principales: Anusim, Nwabundo, Smalley, Melanie, Zimmer, Markie Sue, Lang, Doyle, Jindal, Vishal, Ahaneku, Hycienth O, Gupta, Ruby, Franklin, Candace, Jaiyesimi, Ishmael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2020
Materias:
906.Outcomes Research-Malignant Conditions (Myeloid Disease)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330355/
http://dx.doi.org/10.1182/blood-2020-142784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330355/
http://dx.doi.org/10.1182/blood-2020-142784

Ejemplares similares